Phase II trial of bevacizumab, gemcitabine, oxaliplatin in patients with metastatic pancreatic adenocarcinoma

4113 Background: The combination of gemcitabine and oxaliplatin (GemOx) is a highly active regimen in pancreatic cancer. A recent study with the biologic agent, bevacizumab, and gemcitabine has als...